Abstract. serves an important role in cancer development and growth. However, little is known about the role of miR-375 in the regulation of oral squamous cell carcinoma (OSCC) metastasis and invasion. The present study measured the expression levels of miR-375 in Tca8113, UM2, UM1 and CAL-27 cell lines, using reverse transcription-quantitative polymerase chain reaction. The results demonstrated that miR-375 expression levels were significantly reduced in UM1 and CAL-27 (highly metastatic) compared with Tca8113 and UM2 (less aggressive) OSCC cell lines. Furthermore, it was revealed that overexpression of miR-375 suppressed the migration and invasion of UM1 cells. Based on a luciferase reporter assay, platelet-derived growth factor-A (PDGF-A) was identified as a direct target gene of miR-375. Additionally, overexpression of PDGF-A significantly reversed the effect of miR-375 on cell migration and invasion in UM1 cells. These data demonstrated that miR-375 suppressed OSCC cell migration and invasion by targeting PDGF-A, which may be a potential therapeutic target for the treatment of OSCC.
To explore the possible mechanism of weight loss in Parkinson's disease (PD). Bilateral injections of 6‐hydroxydopamine (6‐OHDA) into substantia nigra (SN) were performed to induce the PD model rats. The rotarod test, food intake, body weight, and interscapular brown adipose tissue (IBAT) weight were recorded 6 weeks postoperation. HE staining was performed to observe the morphology of multilocular adipose cells in IBAT. Immunohistochemistry and western blot were used to determine the protein levels of tyrosine hydroxylase (TH) in the SN, and the levels of uncoupling protein 1 (UCP1), peroxisome proliferator‐activated receptor gamma coactivator‐1α (PGC‐1α), phosphorylated‐hormone sensitive lipase (p‐HSL), HSL, TH, β3‐adrenergic receptor (β3‐AR), cyclic adenosine monophosphate (cAMP), and protein kinase A (PKA) in IBAT. After treatment with 6‐OHDA for 6 weeks, 6‐OHDA rats exhibited decreased TH expression in SN accompanied with shortened staying time on the rotating rod. This motor impairment paralleled with no significant alteration in body mass, IBAT weight, and food intake until the end of the experimental protocol. However, the decreasing diameter of the single fat vesicle in IBAT was observed in the 6‐OHDA group. Meanwhile, compared with the control group, the protein expression of UCP1, PGC‐1α, p‐HSL, TH, β3‐AR, cAMP, and PKA in IBAT were increased significantly in the 6‐OHDA group, whereas no obvious change in the expression of HSL. The present study suggested an increased energy expenditure and activation of the β3‐AR‐cAMP‐PKA signaling pathway in the IBAT after the destruction of the dopamine system in the SN of the rat.
Background and Objectives: Tracking of the tumor progression by MSCs-based therapy is being increasingly important in evaluating relative therapy effectively. Herein, Bioluminescence imaging (BLI) technology was used to dynamically and quantitatively track the hepatocellular carcinoma suppressive effects by human umbilical cord mesenchymal stem cells (UC-MSCs). Methods and Results: The stem cells present typical phenotypic characteristics and differentiation ability by morphology and flow cytometry analysis of marker expression. Then, the growth inhibition effect of conditioned medium and UC-MSC on H7402 cells was studied. It is found both the conditioned medium and UC-MSC can effectively decrease the proliferation of H7402 cells compared with the control group. Meanwhile, the relative migration of UC-MSC to H7402 is also increased through the transwell migration assay. In addition, a mice hepatoma tumor model was built by H7402 cells which can express a pLenti-6.3/DEST-CMV-luciferase 2-mKate2 gene. The effect of stem cells on growth inhibition of tumor in a mice transplantation model was dynamically monitored by bioluminescence imaging within 5 weeks. It has shown the bioluminescence signal intensity of the tumor model was significantly higher than that of the UC-MSC co-acting tumor model, indicating that the inhibition of UC-MSC on liver cancer resulted in low expression of bioluminescent signals. Conclusions: The microenvironment of UC-MSCs can effectively inhibit the growth of liver cancer cells, and this therapeutic effect can be dynamically and quantitatively monitored in vivo by BLI. This is of great significance for the imaging research and application of stem cells in anticancer therapy.
All-inorganic lead halide perovskite nanocrystals (NCs) have been widely investigated as highly promising optical gain materials due to their compelling electrical and optical properties. Although many efforts have been carried out, a deep understanding of perovskite NC vertical-cavity surface-emitting lasers (VCSELs) is elusive, which is very important in the development of photoelectronic integrated circuits. Along these lines, in this work, a low lasing threshold (22 μJ/cm2) single-mode VCSEL consisting of CsPbBr3 NCs film and two distributed Bragg reflectors was successfully constructed. The CsPbBr3 NCs were synthesized by using the supersaturated recrystallization method. Interestingly, benefiting from the strong coupling between the active layer and the optical field in the cavity, a single-mode lasing at 527 nm was demonstrated under femtosecond optical pumping. The carrier dynamics of the perovskite NC VCSEL was also thoroughly investigated by performing pump intensity-dependent time-resolved photoluminescence measurements. The typical gain-switching phenomenon was observed with an ultrafast decay of the laser pulse of ∼10 ps. Our work provides valuable insights for the implementation of the CsPbBr3 NC VCSEL for various optoelectronic applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.